![U.S. FDA Approves Expanded Indication for VONVENDI [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease](https://i3.wp.com/mms.businesswire.com/media/20250905840795/en/1247790/22/Takeda_Red_Logo_2021.jpg?w=420&resize=420,280&ssl=1 "U.S. FDA Approves Expanded Indication for VONVENDI [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease"){kind=logo}
U.S. FDA Approves Expanded Indication for VONVENDI [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease
− Approval Expands Use of VONVENDI to Include Routine Prophylaxis to Reduce…
ADNOC Gas Announces Record Second Quarter Performance, Demonstrating Resilience in Lower Price Environment
Highest-ever quarterly net income of $1.385 billion, up 16% YoY, reflects the…
FDA Approves Apellis EMPAVELI (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older
Proven efficacy across all three key markers of disease—68% reduction in proteinuria,…
